Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine

Анотація

Background. Health technology assessment (HTA) introduction and implementation for development of the National List of Essential Medicines (NLEM) took place in Ukraine in 2016 in the context of National Drug Policy until 2025. The study aimed to outline the reimbursement of medicines for asthma treatment, market access for innovative medicines, main steps of HTA development in the decision making process in Ukraine in line with the international requirements and future directions. Methods. Literature review was conducted examining legislation database and scientific publications on the study issues in Ukraine: epidemiology of asthma, reimbursement programs, HTA development, affordability of innovative medicines for asthma treatment, market analysis. The study was performed to investigate the practices, processes and policies of value assessment and their impact in Ukraine. Results. In 2016 a legal framework was developed for the elaboration of NLEM and procedures for reference pricing and reimbursement programs. HTA is used for the inclusion medicines on the list based on the applied evidence of quality, efficacy, effectiveness, safety and economic evaluations adhering to the Order of Ministry of Health (MoH). HTA implementation in 2016 consisted of legislation, HTA training for experts of Expert committee of MoH and development of NLEM. Reimbursement programs for cardiovascular diseases, type 2 diabetes (T2D), asthma have started in April 2017 due to the adopted regulations. Conclusions. HTA use in the decision-making in Ukraine will provide an access to innovative medicines for patients and transparent, consistent decision making process in assessing the health technologies for inclusion on regulatory lists and reimbursement programs.

Класифікація

Ідентифікатори

Схожі роботи